Response Letter:

Dear Editor,

We are happy to have received notice that our submitted manuscript has been peer-reviewed and may be considered for publication following the necessary revisions. Below we address all the reviewers' comments and address each issue raised appropriately in a point-by-point response fashion.

Sincerely, The Authors

Reviewer Comments:

Reviewer #1:

Scientific Quality: Grade C (Good)

Language Quality: Grade A (Priority publishing)

Conclusion: Accept (General priority)

Specific Comments to Authors:

The author discusses the treatment of Gliomas from the perspective of molecular

typing, which is innovative and worth learning.

We thank the reviewer for their time and comments. We are glad to receive positive remarks on the article.

(1) Science editor:

- **1 Conflict of interest statement:** No conflict of interest.
- **2 Manuscript's theme:** The topic is within the scope of the journal.
- **3 Academic misconduct:** No academic misconduct was found.
- **4 Scientific quality:** The authors submitted a manuscript reviewing management of gliomas in the molecular age. The manuscript is overall qualified.
- (1) Advantages and disadvantages: The reviewers have given positive peer-review reports for the manuscript. Scientific Classification: Grade C; Language Quality: Grade A. The author discusses the treatment of gliomas from the perspective of molecular typing, which is innovative and worth learning.
- **(2) Table(s) and figure(s)**: There are 5 figures, and all should be improved.
- (3) References: A total of 135 references are cited, including 22 published in the last 3 years. There are no self-cited references of the authors. The cited references are overall sufficient and reasonable. The reviewer didn't request the authors to cite improper references published by him/herself.
- **5 Language evaluation:** The English-language is Grade A (Priority publishing).
- 6 Specific comments:
- (1) The "Author Contributions" section is missing. Please provide the author contributions;

We thank the reviewer for their time and comments. We have provided an author contributions section at the end of the article between the conclusions and references sections. The section is appropriately highlighted.

(2) Please obtain permission for the use of picture(s). If an author of a submission is re-using a figure or figures published elsewhere, or that is copyrighted, the author must provide documentation that the previous publisher or copyright holder has given permission for the figure to be re-published; and correctly indicating the reference source and copyrights. For example, "Figure 1 Histopathological examination by hematoxylin-eosin staining (200 x). A: Control group; B: Model group; C: Pioglitazone hydrochloride group; D: Chinese herbal medicine group. Citation: Yang JM, Sun Y, Wang M, Zhang XL, Zhang SJ, Gao YS, Chen L, Wu MY, Zhou L, Zhou YM, Wang Y, Zheng FJ, Li YH. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(34): 5105-5119. Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc^[6]". And please cite the reference source in the references list. If the author fails to properly cite the published or copyrighted picture(s) or table(s) as described above, he/she will be subject to withdrawal of the article from BPG publications and may even be held liable.

All images utilized in figures are from articles licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as appropriate credit to the original author(s) and the source are provided. The reference source for each figure has been cited in the reference list and highlighted appropriately.

(3) Please provide the PubMed numbers (https://pubmed.ncbi.nlm.nih.gov/) to the reference list and list all authors of the references. If a reference has no PMID or DOI, please provide the source website address of this reference;

All references were adjusted to include DOI or the source website address if no DOI or PMID was found and are highlighted appropriately.

7 Recommendation: Conditional acceptance.

Language Quality: Grade A (Priority publishing)

Scientific Quality: Grade C (Good)

(2) Company editor-in-chief:

I have reviewed the Peer-Review Report, full text of the manuscript, all of which have met the basic publishing requirements of the *World Journal of Clinical Oncology*, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors.

When revising the manuscript, it is recommended that the author supplement and improve the highlights of the latest cutting-edge research results, thereby further improving the content of the manuscript. To this end, authors are advised to apply PubMed, or a new tool, the *RCA*, of which data source is PubMed. *RCA* is a unique artificial intelligence system for citation index evaluation of medical science and life science literature. In it, upon obtaining search results from the keywords entered by the author, "Impact Index Per Article" under "Ranked by" should be selected to find the latest highlight articles, which can then be used to further improve an article under preparation/peer-review/revision. Please visit our *RCA* database for more information at: https://www.referencecitationanalysis.com/, or visit PubMed at: https://pubmed.ncbi.nlm.nih.gov/.

We thank the editor-in-chief for their review and are grateful for conditional acceptance of the manuscript. All revisions to the manuscript have been complete based on comments from "Reviewer 1" and the "Science editor". No additional supplementation to the manuscript content was made as all clinical trials referenced are currently still underway and new research results can be reported at this time. We hope these revisons are satisfactory and look forward to the opportunity to contribute to the journal and field at large.